TriSalus Life Sciences Inc (TLSI) Q4 2025 Earnings Call Transcript

Why It Matters

The earnings underscore TriSalus' accelerating commercial traction and improved cash efficiency, positioning the firm to achieve profitability as its PEDD platform expands across new indications.

Key Takeaways

• Revenue up 57% YoY to $11.6M.
• Gross margin fell to 84% due to new launches.
• Adjusted EBITDA loss narrowed to $5.4M.
• Unique accounts grew 30% with 20 new customers.
• CMS code C8004 doubles reimbursable mapping procedures.

Pulse Analysis

TriSalus’ Q3 results illustrate how a focused commercial strategy can translate rapid top‑line growth into tangible financial improvements. The 57% revenue surge was driven primarily by deeper penetration of the TriNav platform in liver embolization and the recent CMS reimbursement expansion. By securing the new HCPCS code C8004, the company unlocked a broader set of billable procedures, effectively doubling the reimbursable use of its technology and fueling account acquisition. This regulatory win not only validates the clinical utility of pressure‑enabled drug delivery (PEDD) but also creates a scalable revenue engine for future product extensions.

Operationally, TriSalus demonstrated disciplined cost management despite higher R&D outlays linked to study closures. Gross margin contraction to 84% reflects the inevitable learning curve associated with launching TriNav FLEX and upcoming TriNav XP, yet management expects margin recovery as manufacturing processes stabilize. The reduction in cash burn to $3.7 million and a robust cash balance of $22.7 million provide a comfortable runway to fund ongoing clinical trials in uterine artery embolization, genicular artery embolization, and thyroid applications. The strategic out‑licensing of nalotolimod further trims development spend while preserving upside potential through partnership deals.

Looking ahead, the reaffirmed 50% revenue growth guidance and the target of positive adjusted EBITDA in the first half of 2026 signal confidence in the platform’s scalability. Expansion into high‑volume indications such as knee osteoarthritis and thyroid nodules could diversify the addressable market beyond oncology, mitigating concentration risk. Investors should monitor the commercialization of TriNav XP and the outcomes of multicenter studies, as successful data readouts will likely accelerate adoption and strengthen TriSalus’ positioning as a leading PEDD technology provider.